2nd Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$530,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; S. 2327 - Seniors Prescription Drug Relief Act; H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R.5260 - Reduced Costs and Continued Cures Act; Prescription Drug pricing legislation - Build Back Better Act - H.R. 5376 & Senate amendments Ensure patient access to behavioral health services and treatments through telehealth

LobbyistCovered position, as disclosed
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 19 (117th), H.R. 5376 (117th), S. 2327 (117th), H.R. 5260 (117th), H.R. 3 (117th)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Justice, Dept of (DOJ); Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Veterans Affairs, Dept of (VA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 955 (117th)

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS)

Bills named: H.R. 8256 (117th), S. 4348 (117th), H.R. 8294 (117th), H.R. 7667 (117th), H.R. 8295 (117th), H.R. 8238 (117th), H.R. 8262 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.